Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07141589

Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries

Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries, A Prospective Double-blinded Randomized Controlled Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
168 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aims to compare the efficacy of ketorolac and fentanyl as adjuvants to local anesthetics for anterior segment surgeries of the eye.

Detailed description

Regional anesthesia for eye surgery includes peribulbar, retrobulbar, and sub-Tenon's blocks. Peribulbar block is commonly used due to a lesser incidence of serious complications such as globe perforation and retrobulbar hemorrhage. Fentanyl is a synthetic opioid widely used as an adjuvant to local anesthetics to prolong its action and provide better postoperative analgesia. fentanyl fastens lid and globe akinesia and provides a better akinesia score. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces the release of inflammatory mediators such as prostaglandins, thereby reducing afferent sensitivities and finally reducing pain. It is devoid of narcotic analgesic adverse effects such as sedation, nausea, and respiratory depression.

Conditions

Interventions

TypeNameDescription
DRUGLidocaine + Bupivacaine + HyaluronidasePatients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU diluted in normal saline to a total volume of 8 ml.
DRUGFentanyl + Lidocaine + Bupivacaine + HyaluronidasePatients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU and fentanyl 20 μg diluted in normal saline to a total volume of 8 ml.
DRUGKetorolac + Lidocaine + Bupivacaine + HyaluronidasePatients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, hyaluronidase 60 IU, and ketorolac 15 mg diluted in normal saline to a total volume of 8 ml.

Timeline

Start date
2024-08-25
Primary completion
2025-11-25
Completion
2025-11-25
First posted
2025-08-26
Last updated
2025-08-26

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07141589. Inclusion in this directory is not an endorsement.